Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Join | Sign in
Home>Videos>This Video
  Videos

Return

Tumour Regression after Intravenous Administration of Novel Tumour-targeted Nanomedicines
SELECTBIO

The possibility of using genes as medicines to treat cancer is limited by the lack of safe and efficacious delivery systems able to deliver therapeutic genes selectively to tumours by intravenous administration, without secondary effects to healthy tissues. In order to remediate to this problem, we investigated if the conjugation of the polypropylenimine dendrimer to transferrin, whose receptors are overexpressed on numerous cancers, could result in a selective gene delivery to tumours after intravenous administration, leading to an increased therapeutic efficacy. The objectives of this study are to evaluate the targeting and therapeutic efficacies of a novel transferrin-bearing polypropylenimine dendrimer. The intravenous administration of transferrin-bearing polypropylenimine polyplex resulted in gene expression mainly in the tumours. Consequently, the intravenous administration of the delivery system complexed to a therapeutic DNA encoding TNF led to a rapid and sustained tumour regression over one month (90% complete response, 10% partial response on A431 human epidermoid tumours). It also resulted in tumour suppression for 60% of PC-3 and 50% of DU145 prostate tumours. The treatment was well tolerated by the animals, with no apparent signs of toxicity. Transferrin-bearing polypropylenimine is therefore a highly promising delivery system for cancer therapy

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
More DNA & Extra Copies of Disease Gene in Alzheimer’s Brain Cells
Scientists at The Scripps Research Institute (TSRI) have found diverse genomic changes in single neurons from the brains of Alzheimer’s patients, pointing to an unexpected factor that may underpin the most common form of the disease.
Epigenetic Study Highlights Drug Targets for Allergies and Asthma
Scientists have discovered over 30 new genes that predispose people to allergies and asthma, some of which could be targets for new drugs.
Partek Milestone: Cited in Over 3,000 Peer-reviewed Articles
Topics include differential gene expression, gene-annotation enrichment analysis, and copy number analysis studies.
Acetate Supplements Shown to Speed Up Cancer Growth
A major compound produced in the gut by host bacteria.
Bacterial Defense Mechanism Targets Duchenne Muscular Dystrophy
Gene therapy approach could treat 60 percent of Duchenne Muscular Dystrophy patients.
Researchers Map Epigenome of More Than 100 Tissue and Cell Types
Researchers provide new insight into which parts of the genome are used to make a particular type of cell.
Epigenomics of Alzheimer’s Disease Progression
Study of epigenomic modifications reveals immune basis of Alzheimer's disease.
Link Between Powerful Gene Regulatory Elements and Autoimmune Diseases Revealed
Findings point to potential drug targets.
Single-Cell, 42-plexed Protein Analysis Achieved with a New Microchip Technology
A novel microdevice capable of detecting 42 unique immune effector proteins has been developed.
Protein Clue To Sudden Cardiac Death
A protein has been shown to have a surprising role in regulating the 'glue' that holds heart cells together, a finding that may explain how a gene defect could cause sudden cardiac death.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters